{"id":389300,"date":"2023-02-07T00:00:00","date_gmt":"2023-02-07T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0001-2022-biopharma-alzheimers-disease-disease-landscape-forecast-g7-2022\/"},"modified":"2026-04-22T05:17:16","modified_gmt":"2026-04-22T05:17:16","slug":"dlsfcg0001-2022-biopharma-alzheimers-disease-disease-landscape-forecast-g7-2022","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0001-2022-biopharma-alzheimers-disease-disease-landscape-forecast-g7-2022\/","title":{"rendered":"Alzheimer&#8217;s Disease | Disease Landscape &#038; Forecast | G7 | 2022"},"content":{"rendered":"<p>In June 2021, Biogen \/ Eisai\u2019s anti-A\u03b2 MAb Aduhelm received accelerated approval from the FDA for the treatment of Alzheimer\u2019s disease (AD), making it the first potential DMT approved for this disease\u2014an event marked by considerable controversy. Other DMTs may soon follow in the United States and potentially other markets (Eisai \/ Biogen\u2019s lecanemab, Eli Lilly\u2019s donanemab, and Novo Nordisk\u2019s semaglutide). Meanwhile, hope remains for therapies from Lundbeck, Otsuka, Avanir, BioXcel, and Axsome that are in late-phase development to treat key neuropsychiatric symptoms associated with AD. The launch of these potential blockbusters could meaningfully alter the dynamics of this market, driven by clear need, strong market demand, and premium pricing.<\/p>\n<p>QUESTIONS ANSWERED<\/p>\n<ul>\n<li>How large is the treatable AD population? What will be the impact of future anti-A\u03b2 MAbs on diagnosis \/ drug treatment rates if these agents become available and accessible for the treatment of early AD?<\/li>\n<li>What are KOLs\u2019 opinions of recently launched therapies (e.g., Corium\u2019s Adlarity) and other key symptomatic and disease-modifying therapies in development for AD?<\/li>\n<li>What commercial uptake can Rexulti, AVP -786, Auvelity (AXS-05) expect if they launch for AD agitation?<\/li>\n<li>What are the drivers and constrainers of the AD market, and how might they change over the forecast period as premium-priced agents enter the market?<\/li>\n<\/ul>\n<p>PRODUCT DESCRIPTION<\/p>\n<p><em>Disease Landscape &#038; Forecast<\/em> provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p>SOLUTION ENHANCEMENT<\/p>\n<p><em>Disease Landscape &#038; Forecast<\/em> features will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.<\/p>\n","protected":false},"template":"","class_list":["post-389300","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-alzheimers-disease","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389300","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389300\/revisions"}],"predecessor-version":[{"id":576124,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389300\/revisions\/576124"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389300"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}